09969 INNOCARE
- 4.990
- -0.140-2.73%
INNOCARE News
Goldman Sachs: Target price raised to HK$8.6 for the “Buy” rating for Nuocheng Jianhua (09969)
Goldman Sachs raised Nuochengjianhua's (09969) sales forecast for the full year of this year from 817 million yuan to 839 million yuan.
Nuochengjianhua (9969.HK) 2024 Quarterly Report Review: Performance is in line with expectations, and obutinib is expected to grow at a high rate throughout the year
Introduction to this report: 2024Q1 obutinib's revenue is 164 million yuan (+9%). Clinical progress for hematomas, immunization, and solid tumors is progressing smoothly. Various drugs are expected to be submitted for NDA in 2024. We are optimistic about the company's future development and maintain “growth”
InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.
Express News | Science and Technology Innovation Board Review: The Science and Technology Innovation 50 Index closed down 1.42%, and the software sector sentiment is sluggish
Express News | CITIC Construction Investment: The national biotechnology and biomanfacture action plan is expected to be introduced in the near future, and the subsequent implementation of the policy is worth looking forward to
Innocare Pharma Posts Q1 Loss
Innocare Pharma (HKG:9969) posted a loss attributable to shareholders of 142.4 million yuan, or 0.08 yuan per share, for the first quarter, according to a Monday filing with the Hong Kong Exchange. Op
Featured announcements | Tencent Music's adjusted net profit increased by 23.9%; King's Rui: Legendary Biotech's net loss narrowed
China Life Insurance: The cumulative original premium income for the first 4 months was about 371.2 billion yuan, an increase of 3.9% over the previous year; China Resources Land: The cumulative contract sales amount for the first 4 months was approximately RMB 72.0 billion.
Nuochengjianhua Pharmaceutical Co., Ltd. report for the first quarter of 2024
InnoCare Logs Loss in Q1
InnoCare (SHA:688428, HKG:9969) recorded an attributable loss of 142.4 million yuan for the first quarter of 2024, a Monday filing on the Hong Kong bourse said. Diluted loss per share for the three mo
Nuochengjianhua (09969.HK) R&D investment increased 26.09% in the first quarter, gross margin rose to 85.4%, holding about 8.2 billion yuan in monetary capital
Gelonghui, May 13 | Nuocheng Jianhua (09969.HK) announced that it achieved a total operating revenue of RMB 166 million from January to March 2024. At the same time, the company continued to raise its gross profit level. The gross margin for January-March 2024 was 85.4%, an increase of 8.1 percentage points over 77.3% in the same period last year. The total R&D investment during this period was 178 million yuan, an increase of 26.09% over the previous year. Sales revenue of the company's core product, obutinib (INOC), continued to grow. From January to March 2024, sales revenue totaled RMB 164 million, an increase of 9% over the previous year. Entering 2024, accompanied by
諾誠健華：2024年第一季度季度報告
Express News | Nuocheng Jianhua: Net profit loss of 142 million yuan in the first quarter of 2024
InnoCare Pharma Sees Insider Stock Selling
From what we can see, insiders were net sellers in InnoCare Pharma Limited's (HKG:9969 ) during the past 12 months. That is, insiders sold the stock in greater numbers than they purchased it. While
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Changes in Hong Kong stocks | Cornerstone Pharmaceutical-B (02616) rose more than 26%, leading the innovative drug concept, ASCO catalyzes market conditions, institutions are optimistic about policy+health insurance marginal improvement
Zhitong Finance App learned that innovative drug concept stocks showed strong performance. As of press release, Cornerstone Pharmaceutical-B (02616) rose 26.14% to HK$1.11; Cansino Biotech (06185) rose 16.91% to HK$20.95; Gacos-B (01167) rose 14.2% to HK$1.93; Nuocheng Jianhua (09969) rose 12.31% to HK$5.2; Rongchang Biotech (09995) rose 10.2% to HK$30.8. According to the news, the research title of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was on April 25
Nuocheng Jianhua (09969.HK) will hold a board meeting on May 13 to approve the first quarter results
Glonghui, April 29, 丨 Nuochengjianhua (09969.HK) announced that the company will hold a board meeting on May 13, 2024 to consider and approve the unaudited first quarter results of the company and its subsidiaries for the three months ended March 31, 2024 and their announcements.
Capital from the south will cross the Hong Kong River again! What is the “success” of the individual stocks listed in AH and AH?
① Among AH listed companies, the target with the highest premium rate reached 6 times; ② the individual stocks with the most significant performance improvement in 2023 among AH listed companies came from the power equipment industry; ③ H shares in AH listed companies account for relatively high targets mainly central state-owned enterprises.
Nuocheng Jianhua (688428): Hematoma first-mover advantage stabilizes the self-immunity pipeline and the harvest period is approaching
Nuochengjianhua (688428.SH) is a commercial-stage biomedical company. Since its establishment in 2015, 2 hematoma products have been approved for sale, and 13 products are in the clinical stage, covering hematomas, immune diseases, and
InnoCare Pharma Limited Expects Multiple Drug Products to Reach Approval
諾誠健華：二零二三年年報
Analysis
Price Target
No Data
